What is the recommended dosage and regimen of clomiphene citrate (Clomid) for a male with secondary hypogonadism or infertility?

Clomiphene Citrate Dosing for Male Hypogonadism and Infertility

For men with secondary hypogonadism who desire fertility preservation, start clomiphene citrate 25 mg orally daily (or 50 mg every other day), and if pure enclomiphene is available, use 12.5–25 mg daily instead. 1, 2

---

Diagnostic Confirmation Before Initiating Therapy

• Confirm biochemical hypogonadism with two separate morning total testosterone measurements (8–10 AM) showing levels < 300 ng/dL. 1
• Measure LH and FSH after confirming low testosterone; low or low‑normal LH/FSH with low testosterone indicates secondary (hypogonadotropic) hypogonadism, which predicts favorable response to clomiphene. 1, 3
• Obtain baseline semen analysis to document fertility potential before starting therapy. 2
• Measure prolactin to exclude hyperprolactinemia, which can cause secondary hypogonadism and requires different management. 1
• Check thyroid function (TSH) because thyroid disorders commonly disrupt the hypothalamic‑pituitary‑gonadal axis and can mimic hypogonadal symptoms. 1

---

Standard Dosing Protocol

Initial Regimen

• Start clomiphene citrate 25 mg orally once daily (or 50 mg every other day if daily dosing is not tolerated). 4
• If pure enclomiphene citrate is available, use 12.5–25 mg orally once daily, as it lacks the estrogenic zuclomiphene isomer and may have fewer side effects. 2

Dose Escalation

• If testosterone remains suboptimal (< 450 ng/dL) and symptoms persist after 2–3 months on 25 mg daily, increase to 50 mg daily. 4
• Higher doses (50 mg daily) may be effective in men who do not respond to 25 mg, though this increases the risk of elevated estradiol and side effects. 4

Duration of Therapy

• Administer for 6–9 months to assess maximal response in semen parameters and testosterone levels. 4
• Long‑term use beyond 3 years is safe and effective, with 88% of men achieving eugonadism and 77% reporting improved symptoms. 5

---

Monitoring Requirements

Early Follow‑Up (First 3 Months)

• At 6–8 weeks: measure total testosterone, LH, FSH, and estradiol to confirm hormonal response. 2, 5
• At 3 months: repeat semen analysis to assess improvement in sperm concentration and total motile count. 6
• Target testosterone levels in the mid‑normal range (450–600 ng/dL). 1

Long‑Term Monitoring (After 3 Months)

• Every 3–6 months during the first year: repeat testosterone, LH, FSH, estradiol, and semen analysis. 2
• Annually once stable: continue monitoring testosterone and semen parameters to ensure sustained response. 5
• Monitor estradiol levels because clomiphene significantly increases estradiol, which can cause gynecomastia or mood changes in some men. 5

---

Expected Outcomes

Hormonal Response

• 88% of men achieve eugonadism (testosterone > 300 ng/dL) with long‑term clomiphene therapy. 5
• Testosterone levels typically rise from baseline (< 300 ng/dL) to mid‑normal range (450–600 ng/dL). 5

Semen Parameter Improvement

• Sperm concentration improves significantly, from a median of 14 million/mL to 21 million/mL (p = 0.002). 6
• Total motile count (TMC) increases from a median of 13 million to 28 million (p = 0.04). 6
• One‑third of men with TMC < 5 million improve to TMC > 5 million, expanding reproductive options to include intrauterine insemination (IUI). 6

Symptom Improvement

• 77% of men report improved hypogonadal symptoms (libido, energy, erectile function) with long‑term clomiphene use. 5

---

Absolute Contraindications

• Never prescribe exogenous testosterone to men desiring fertility, as it suppresses LH and FSH through negative feedback, causing oligospermia or azoospermia that can take months to years to recover. 1, 2
• Primary hypogonadism (elevated LH/FSH with low testosterone) is a contraindication, as the testes cannot respond to increased gonadotropin stimulation. 3
• Active desire for fertility with complete AZFa or AZFb Y‑chromosome microdeletions contraindicates clomiphene, as these deletions predict near‑zero sperm retrieval success. 3

---

Side Effects and Management

Common Side Effects (8% Incidence)

• Mood changes (5% of long‑term users). 5
• Blurred vision (3% of long‑term users). 5
• Breast tenderness or gynecomastia (2% of long‑term users), related to elevated estradiol. 5

Management of Elevated Estradiol

• If estradiol rises excessively (> 50 pg/mL) and causes gynecomastia or mood symptoms, consider adding an aromatase inhibitor (e.g., anastrozole 0.5 mg twice weekly) or reducing clomiphene dose. 3
• Alternatively, switch to pure enclomiphene (12.5–25 mg daily) if available, as it lacks the estrogenic zuclomiphene isomer. 2

---

When Clomiphene Is Insufficient

Failure to Respond After 6–9 Months

• If testosterone remains < 450 ng/dL or semen parameters do not improve after 6–9 months on 50 mg daily, switch to gonadotropin therapy (hCG 1,500–3,000 units subcutaneously 2–3 times weekly, with or without recombinant FSH 75–150 units 2–3 times weekly). 1, 2
• Gonadotropin therapy is the guideline‑recommended first‑line treatment for secondary hypogonadism with fertility concerns, but clomiphene represents a practical off‑label alternative when gonadotropins are not feasible. 2

Assisted Reproductive Technology (ART)

• If semen parameters remain severely impaired (TMC < 5 million) despite clomiphene, proceed directly to IVF/ICSI, as it offers superior pregnancy rates compared to empiric hormonal therapy. 1, 2
• Sperm cryopreservation (banking 2–3 ejaculates) should be performed before any future gonadotoxic exposures or if considering eventual testosterone therapy. 2

---

Critical Pitfalls to Avoid

• Do not diagnose hypogonadism on a single testosterone measurement; require two separate morning values (8–10 AM). 1
• Do not omit LH/FSH testing after confirming low testosterone, as the distinction between primary and secondary hypogonadism directs therapy and fertility counseling. 1, 3
• Do not prescribe clomiphene to men with primary hypogonadism (elevated LH/FSH), as the testes cannot respond to increased gonadotropin stimulation. 3
• Do not start exogenous testosterone in men desiring fertility, as it causes azoospermia. 1, 2
• Do not ignore elevated estradiol, as it can cause gynecomastia and mood changes; monitor estradiol levels regularly. 5

---

Patient Selection: Who Benefits Most?

• Men with secondary hypogonadism (low testosterone with low or low‑normal LH/FSH) are the best candidates. 1, 2
• Men with adult‑onset idiopathic hypogonadotropic hypogonadism respond particularly well, with 75% achieving pregnancies on clomiphene alone. 7
• Men with oligospermia (sperm concentration 5–15 million/mL) show clinically useful response rates, with one‑third improving to TMC > 5 million. 6
• Baseline patient characteristics, hormone profiles, and degree of oligospermia do not predict treatment response, so a trial of clomiphene is reasonable in most men with secondary hypogonadism. 6